Big Pharma's Key Lifecycle Management Strategies - Maximizing the
...
segments and geographic markets poised for strong growth. - Reinforce R&D pipelines by identifying .... Figure 36: Herceptin Worldwide Sales, $m, 1999–2008 ...
http://www.researchandmarkets.com/reports/1199222/big_pharmas_key_lifecycle_management.pdf
Biopharmaceuticals - Current Market Dynamics and Future Outlook
It also provides sales and growth rate figures for the following leading biopharmaceutical products ... Neupogen (2002 - 2004) Geographical Breakdown of Market Revenue ... Herceptin (2000 – 2004) Combined Global Revenue & Growth Rates ...
http://www.researchandmarkets.com/reports/39083/biopharmaceuticals_current_market_dynamics.pdf
Big Pharma's Key Lifecycle Management Strategies - Maximizing the
...
Table 20: Avastin Worldwide Sales, $m, 2004'2008 60. Table 21: Herceptin Worldwide Sales, $m, 1999'2008 62. Table 22: Rituxan Worldwide Sales, $m, ...
http://www.reportlinker.com/p0175984/Big-Pharma-s-Key-Lifecycle-Management-Strategies-Maximizing-the-Market-Potential.pdf
F. Hoffmann-La Roche Ltd.: PharmaVitae Profile - Download this
...
Table 38: Herceptin: sales forecast ($m), 2007-13 149 ... Figure 17: Roche prescription pharmaceutical sales by geographic region ($m), 2001-13 91 ...
http://www.reportlinker.com/p0118492/F-Hoffmann-La-Roche-Ltd-PharmaVitae-Profile.pdf
New Cancer Therapeutics
Estimated worldwide number of new cancer cases and deaths by type of cancer (in thousands)* ... Herceptin: global sales 2000–05. 142. Table 4.25: ...
http://www.globalbusinessinsights.com/content/rbhc0083t.pdf
The Cancer Market Outlook To 2014: Competitive landscape, market
...
Avastin, Herceptin, Tarceva and Xeloda). Roche's strength in the cancer market has been bolstered by its ... cancer segment, the seven largest geographic .... Global cancer market sales forecast. CHAPTER 4 PIPELINE ANALYSIS. • Summary ...
http://www.globalbusinessinsights.com/content/rbhc0248m.pdf
GTCB Corp Presentation February 2010 020810
Geographical distribution. ▪ Build on Existing Strategic Relationships .... Worldwide Sales ($Billions). '01 '02 '03 '04 '05 '06 '07 '08. MAb Sales 2001 – 2008. (Rituxan, Humira, Erbitux & Herceptin) ...
http://www.transgenics.com/GTCB Corp Presentation January 2010.pdf
The Global
Protein Therapeutics Market
Table 6.11 Global Sales of Herceptin 2000-2005. Table 6.12 Global Sales of Humira 2003-2005 ... Graph 5.3 Humulin Sales by Geographical Region (2005) ...
http://www.spectraintelligence.com/proteintheratoc.pdf
Cancer
Therapeutics 2006
Table 2.2 Rates of Incidence and Deaths for Select Cancers Worldwide, 2000 ... Table 3.1 Sales of Top Oncology Drugs Indicated for Colorectal, Prostate, ...
http://www.spectraintelligence.com/cancertoc.pdf
Peter Blume
Jensen - Medicon Valley Alliance
5 May 2009 ... Geographical and financial specifics dictate in-licensing and M&A ... Herceptin (trastuzumab). Rituxan/MabThera (rituximab). Remicade (inhlixirnab). Projected 2007 worldwide sales ($MM). Centocor/Schering-Plough/ ...
http://www.mva.org/media(3572,1033)/Blume-Jensen.pdf
Biomarker Technology Platforms for Cancer Diagnoses and
Therapies
Figure 3.3: Geographical Distribution of Cancer Tumor Diagnostic Testing 55 ... Table 2.15: Herceptin Worldwide Sales, 1999-2007 34 ...
http://researchandmarkets.co.uk/reports/562564/biomarker_technology_platforms_for_cancer.pdf
The Pharmaceutical Market Outlook to 2015: Implementing innovative
...
increasing aging population, and emerging geographical markets such as China and India. .... Case study: Herceptin – a targeted therapeutic for breast cancer ... Table 4.7: Sales in the global and US markets by sector, 2004 ...
http://www.researchandmarkets.co.uk/reports/302088/the_pharmaceutical_market_outlook_to_2015.pdf
Cancer Therapeutics 2006: Market Dynamics and R&D Trends
...
1 Dec 2005 ... Product, Company and Geographic Market Analysis ... Herceptin. 7.2.1.3. Arimidex ... Rates of Incidence and Deaths for Select Cancers Worldwide, 2000. Table 2.3 .... Breast Cancer, by Global Sales 20042005. Graph 3.3 ...
http://bio4eu.jrc.ec.europa.eu/documents/CancerTherapeutics2006.pdf
WELCOME!
By Geographic Area. The global pharmaceutical market generated. $555.5 billion in revenue in 2006. This value reflects a 4.9% growth in sales for 2006. The ...
http://pharmaclub.rutgers.edu/newsletter/Oct 2007.pdf
Annual report - Key figures,
Letter to Shareholders
Swiss francs due to strong sales growth and continuing productivity .... geographic atrophy. Phase I. Phase II. Phase III. Registration ... Herceptin adj BC HER2+, 2-yr treatment. RG1273 pertuzumab. mBC HER2+ .... We would like to take this opportunity to thank the more than 80000 Group employees worldwide for the ...
http://www.roche.com/gb09e01.pdf
Roche Building the base for
current and future growth
2 Avastin, Boniva, CellCept, Herceptin, MabThera/ Rituxan, NeoRecormon/ Epogin, Pegasys, Tarceva, Xeloda .... Sales erosion due to generisation (% of 2004 sales) ... Roche: unique geographic risk diversification ...
http://www.roche.com/irp061026.pdf
OPPORTUNITIES AND
BARRIERS IN THE BIOSIMILAR MARKET: EVOLUTION OR ...
by J Pisani - Cited by 7
http://www.ableindia.org/biosimilars.pdf
Pharmacogenomics:
A Step Towards Personalized Medicine
designated geographical area to understand the ..... Herceptin also proves the fact that PGs finds ... Global herceptin sales were of the order of US $ ...
http://www.premasbiotech.com/img/papers/Pharmacogenomics.pdf
1 IMS Supp Sept07
this out: global sales reached. $35 billion last year, with targeted therapies accounting .... Herceptin® by Genentech in 1998 came the first targeted therapy supported by a .... including geographical growth opportunities, mergers and acquisitions, ..... Informed by worldwide experience that spans major and ...
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Static File/Riding_the_Wave.pdf
Microsoft
PowerPoint - FRESCO 2003_Epstein_2003-01-23_Media_web ...
Source: IMS MIDAS worldwide oncology sales. Oncology sales worldwide from date of launch. Glivec®/Gleevec™ 6/01. Herceptin 10/98. Gemzar 6/95. Camptosar 4/94 ... Geographic. Rollout. 14 FRESCO 2003 / David Epstein / 2003-01-23 / Media ...
http://hugin.info/134323/R/1011987/157597.pdf
Half-Year
Report 2007
Solid YTD June Keppra® worldwide sales of 498 million euro growing 36% (or +44% at ..... partially off-set by continuing royalty income on Herceptin® and Avastin®. ...... The Group's primary reporting format is the geographical segment. ...
http://hugin.info/133973/R/1142055/216002.pdf
2004 pro forma combined net sales1: up 10.0% on a comparable
basis
In the fourth quarter, worldwide sales of Actonel® came to 258 million euros, ... whose tumors over-express the Her2 gene, in association with Herceptin®). ... Fourth-quarter proforma combined net sales by geographical region ...
http://en.sanofi-aventis.com/binaries/20050126_PDF_CP_media_tcm28-15533.pdf
Third-quarter 2008 results
31 Oct 2008 ... Third-quarter worldwide sales of Aprovel®/Avapro®/Karvea® were up 11.5% ..... third-quarter and 9-month consolidated net sales by geographic ...
http://en.sanofi-aventis.com/binaries/081031_results_en_tcm28-22502.pdf
BUSINESS INSIGHTS The Pharmaceutical Market Outlook to 2018
drugs, such as Avastin and Herceptin, there are some promising drugs on the horizon. .... Sales by geography, 2006-7. • Percentage of developmental ...
http://industrymatter.com/DatamonitorandBusinessInsightBrochures/DBIB0214brochure.pdf
Microsoft
PowerPoint - BPC_1_HALIOUA_ERIC
23 Oct 2006 ... Worldwide sales of biologics. Worldwide sales of small molecules (SM) ..... antibodies sales by geographic area ...
http://www.eurobio2006.com/DocBD/press/pdf/41.pdf
Microsoft
PowerPoint - BPC_50_SCHWEBIG_ANNICK
25 Oct 2006 ... Geographical market shares ... Worldwide biopharmaceutical sales. Worldwide pharmaceutical sales excluding biodrugs ...
http://www.eurobio2006.com/DocBD/press/pdf/51.pdf
A
Review: Stereochemical consideration and eudismic ratio in ...
by AK PeepliwalaGeographically, the U.S. is the biggest consumer of enantiomeric fine chemicals, ... Table 1: Worldwide sales of single-enantiomer pharmaceutical final products .... Herceptin. Trastuzumab. 2.469. Amgen. Neulasta. Pegfilgrastim ...
http://jbsr.pharmainfo.in/documents/vol2issue1/2010020105.pdf
The Cancer Market Outlook to 2013: Competitive landscape, pipeline
...
were MabThera (32.8%), Herceptin (28.8%), Avastin ..... Worldwide cancer market share by geography ($bn),. 2007. • Sales of cancer brands by ...
http://www.market-research-report.com/datamonitor/images/rbhc0215_rsm.pdf
. New challenges to medicare beneficiary access to mAbs
by J Cohen - 2009seven mAbs had blockbuster status with global sales of over US $1 ... trastuzumab, has slowed because of market saturation, or increased competition. .... the same geographic jurisdiction as both a carrier and fiscal interme- ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715185/pdf/mabs0101_0056.pdf
Microsoft PowerPoint - 980914 鄭安理 臨床腫瘤學
are Expected to Reach $38.9 Billion. 74% of the total top 20 cancer therapy brand sales ... (trastuzumab, cetuximab) tyrosine kinase inhibitors .... Therapy in Asia. – Importance of ethnic and geographical difference ...
http://www.ntuh.gov.tw/onc/下載專區/Shared Documents/98學年臨床腫瘤學教學檔案/980914 鄭安理 臨床腫瘤學.pdf
Sanofi-aventis Press Release
with Herceptin®. Taxotere® achieved third-quarter net sales growth of ... Third-quarter worldwide sales of Aprovel®/Avapro®/Karvea® were up 11.5% at ..... Appendix 2: 2008 third-quarter and 9-month consolidated net sales by geographic ...
http://www.info-financiere.fr/upload/ECO/2008/10/FCECO009156_20081031.pdf
Bio-business in
brief: Many a monoclonal
by R Mehdiratta - 200725 Sep 2007 ... $10 billion in 2004, with six having global sales of over ... India who was told that each injection of herceptin would ..... Notes: National phase: All patent applications have geographical limitations, ...
http://www.ias.ac.in/currsci/sep252007/789.pdf
Ayurveda and
natural products drug discovery
by B Patwardhan - 2004 - Cited by 57
http://www.ias.ac.in/currsci/mar252004/789.pdf
Private and
Public Biotech Companies by Region--2000
5 Feb 2005 ... e.g., Herceptin. Specialty tool and discovery companies enabling ... Worldwide Sales of Other Biomaterials. ■ Heart valves--$683 million ...
http://www.syntexsyvaalumni.org/erbes05.pdf
Sanofi-aventis press release
Geographical split of consolidated net sales by product (Top 15) .... Fourth-quarter worldwide sales of Aprovel®/Avapro®/Karvea® were €480 million, ...
http://www.sanofi-aventis.ca/live/ca/medias/2D3E4753-6A8C-49FB-A820-3A68F0B363B6.pdf
RESULTATS CA Q3 081105 ENG pdf
Net sales by geographical region. Millions of euros. 2005 Q3 net sales. Change on a .... In the 9 months to end September, worldwide sales of Actonel ...
http://www.sanofi-aventis.ca/live/ca/medias/C5B49103-B7F2-48BF-A163-C3D8D59783C4.pdf
ADDRESSING GLOBAL
HEALTH INEQUITIES: AN OPEN LICENSING APPROACH ...
by A Kapczynski - 2004 - Cited by 101
http://www.benkler.org/EALFinalBTLJ.pdf
2007 Annual Report
as geographically. Abbott has long been an international busi- .... net Sales Worldwide*. (dollars in billions) cash Dividends per Share. (dollars per share) ...... Crestor and Herceptin are not trademarks of Abbott Laboratories. ...
http://www.abbott.com/static/content/microsite/annual_report/2007/support_files/Abbott_AR07_editorial.pdf
Abbott 2006 Annual Report
relating to customers, products or geographic locations, except that ...... HUMIRA, which increased its worldwide sales to $2.0 billion in 2006 ...... Crestor and Herceptin are not trademarks of Abbott Laboratories. ...
http://www.abbott.com/static/content/microsite/annual_report/2006/support_files/abbott_ar06_full.pdf
Capturing the India Advantage
30 Nov 2009 ... Such diversity across products, geography and demographics creates ..... Herceptin. Lyrica. Lovenox. Seroquel. Rituxan. Gleevec. Prevnar .... Worldwide sales of expiring products including biologics in year of US patent ...
http://www.indiapharmasummit.com/downloads/reports/Capturing the India Advantage.pdf
Microsoft PowerPoint - 04_Sandoz Day_Presentation_Biosimilar
1 Source: worldwide sales of expiries based on Evaluate Pharma and internal estimates 2007 ... interferons, trastuzumab, rituximab, infliximab and etanercept ... Geographic rollout underway. Niche market, but growing patient pool ...
http://www.biosimilar.sandoz.de/assets/content/de/files/2008-09-Sandoz-Day_Teissl-Presentation.pdf
Lecture at School of Pharmacy, London
25 Nov 2008 ... let alone a guarantee that prices or sales volumes will provide a decent return on ... speeds (according to business mix, geographical spread, near-term growth .... drug Herceptin, developed by Genentech and Roche. ...
http://www.pharmacy.ac.uk/fileadmin/documents/News/Is_there_a_future_for_Big_Pharma.pdf
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of
...
Cancer Incidence and Mortality by Geographical Regions Worldwide .... Table 4.1 Estimated Global Sales (US$) and Forecasts of Leading Cancer Chemo-therapies ...
http://researchandmarkets.net/reports/335548/chemotherapy_market_insights_2006_2016_a.pdf
Microsoft PowerPoint - M Stanley conference Miami ES 02.05.07
rev2
Expanded geographic reach and improved attractiveness for in-licensing. – World-class biotechnology and ... worldwide sales of > € 1 billion in 2006 .... sales. (TEuro) rituximab trastuzumab imatinib paclitaxel docetaxel erlotinib ...
http://www.merck.de/company.merck.de/en/images/M-Stanley-conference-Miami-ES-02.05.07-rev2_tcm82_15452.pdf
Microsoft PowerPoint - Sal.Oppenheim Milan SB JT 24.05.2007
Expanded geographic reach and improved attractiveness for in-licensing. – World-class biotechnology and ... worldwide sales of > € 1 billion in 2006 .... Ex-MNF sales (TEuro) rituximab trastuzumab imatinib paclitaxel docetaxel erlotinib ...
http://www.merck.de/company.merck.de/en/images/Sal.Oppenheim-Milan-SB-JT-24.05.2007_tcm82_15448.pdf?Version=
FEATURE
for Herceptin and Rituxan is primarily due to ..... lion, and their worldwide sales were ~$210 mil- ... category try to sell these products worldwide. ...
http://www.nature.com/nbt/journal/v26/n11/pdf/nbt1108-1227.pdf
ESPACE
institutionally protected niches, geographical proximity is useful but not decisive. The spatial ...... drug, with $2 billion or more in worldwide sales. ...
http://www.sbg.ac.at/gew/Zeller/WP/Espace 2008-7.pdf
Microsoft PowerPoint - Nr. 1_CMD Strategy Pharma & Life
Science
Extension of geographic footprint. Consolidation/scale. Targeted investments in growing segments ... Pharmaceutical sales: Market sizes and growth rates 2008 - .... Prevalence of diabetes worldwide in % of adult population in ... Herceptin (Roche) ! Epogen (Amgen) ! ! Avastin (Roche) ! Humira (Abbott) ...
http://www.gerresheimer.de/uploads/media/Nr._1_CMD_Strategy_Pharma___Life_Science.pdf
Update
Analysis
sales of CHF2.96bn in 2006 and together with. MabThera and Herceptin demonstrates the burgeoning ... geographically dispersed occurrence of avian influenza ..... worldwide. This in turn is essential for the eventual pro- ...
http://www.pharmaprojects.com/subscribers/ua/Dec07UA.pdf
Health
Care and Industry Overview and Challenges
Genetech (Herceptin). Idec-Biogen (Rituxan). Astra-Zeneca (Iressa). Millennium (Velcade) ... four geographic areas; the United States, Europe (European ... lion in worldwide sales ($17.1 B in USA) and 50% of all pre- scriptions in 2002. ...
http://www.springerlink.com/index/T311431Q142148U3.pdf
1 2
